Table 2.
Dynamic alteration of serum sodium levels in cirrhotic patients treated with tolvaptan or placebo
| Tolvaptan (n = 169) | Placebo (n = 61) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 day | 4 days | 7 days | 3 months | 6 months | 0 day | 4 days | 7 days | 3 months | 6 months | |
| Normal sodium, mmol/L (n) | 138.15 ± 2.58 (100) |
140.28 ± 3.07 (95) |
139.83 ± 3.32* (95) |
136.88 ± 5.09* (56) |
136.97 ± 6.92* (49) |
138.60 ± 2.24 (32) |
138.52 ± 2.39 (29) |
138.23 ± 2.16 (24) |
136.97 ± 4.18 (14) |
133.18 ± 9.31 (11) |
| Mild hyponatremia, mmol/L (n) | 132.98 ± 1.31 (44) |
138.02 ± 3.11** (44) |
136.59 ± 3.51** (41) |
133.78 ± 4.13** (33) |
131.96 ± 5.29** (23) |
131.96 ± 1.44 (21) |
131.34 ± 3.03 (13) |
131.06 ± 4.65 (13) |
129.45 ± 6.66 (11) |
134.50 ± 6.20 (9) |
| Middle hyponatremis, mmol/L (n) | 127.35 ± 1.17 (19) |
131.50 ± 2.85** (18) |
132.29 ± 2.87** (18) |
132.24 ± 5.71** (11) |
129.81 ± 7.02** (10) |
127.94 ± 0.92 (7) |
130.30 ± 3.82 (5) |
129.20 ± 10.32 (3) |
134.30 (2) |
139.30 (2) |
| Severe hyponatremia, mmol/L (n) | 120.87 ± 3.33 (6) |
126.87 ± 7.05** (6) |
126.50 ± 6.61** (5) |
131.10 ± 6.15** (3) |
132.30 (2) |
124.80 (1) |
ND | ND | ND | ND |
Compared with 0 day, *P > 0.05, **P < 0.01